ClinicalTrials.gg
Not yet recruitingNCT06497374FACTUpdated Jul 11, 2024

FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack

A Phase 2 interventional study of Efgartigimod Alfa Injection and High-dose intravenous methylprednisolone in Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder and NMO Spectrum Disorder, sponsored by Tianjin Medical University General Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Tianjin Medical University General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital — 5 open to participants now, 8 under way, 3 of them phase 3. Neuromyelitis Optica · Tianjin Medical University General Hospital.

Planned enrollment
6th of 14
63 · median 24
Started
2024
with 1 other
Phase 2
5 of 15
1 open now
Registered
9th of 15
by date

Among the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 9th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

5 of the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, or all of them as a file.
02

Study summary

NMOSD is an autoimmune disease of the central nervous system that predominantly affects the spinal cord and optic nerves. The objectives of this study are to assess the efficacy and safety of FcRn antagonists (efgartigmod) for treatment of patients with neuromyelitis optica spectrum disorders during acute phase who are anti-aquaporin-4 (AQP4) antibody-positive. The potential of efgartigimod, an IgG1 Fc fragment that competes with IgG for FcRn binding, thereby lowering IgG levels, warrants further investigation as a treatment for acute neuromyelitis optica spectrum disorders attacks. This study aims to evaluate the therapeutic potential of efgartigmod in acute NMOSD attack.

03

Conditions studied

  • Neuromyelitis Optica
  • Neuromyelitis Optica Spectrum Disorder
  • NMO Spectrum Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, ages 18 to 75.
  2. Meet the 2015 International Panel of Experts (IPND) diagnostic criteria for neuromyelitis optica spectrum disorders.
  3. Acute EDSS nadir of 2.5-7.5, and a change of at least 0.5 points from baseline due to an acute relapse event.
  4. Confirmation of serum AQP4-IgG antibody positivity using the CBA assay.
  5. Confirmation of an acute attack of neuromyelitis optica spectrum disorders either with an acute optic neuritis and/or acute myelitis, defined as a worsening in the patient's signs and symptoms of neurological/visual impairment, an increase in the EDSS score, and symptoms lasting more than 24 hours and occurring more than 1 month since the last attack. Combination of imaging and clinical evaluation will be used to assess relapse and rule out a pseudorelapse.
  6. New lesions or enhanced lesions need to be found in MRI.
  7. Subjects who were receiving therapy prior to the screening period will be required to agree to discontinue immunosuppression.
  8. Treatment is stable at least 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Other core clinical symptoms besides optic neuritis and myelitis.
  2. Severe neuromyelitis optica spectrum disorder attack, which in the judgment of the investigator is not appropriate for this study. Severe is defined as requiring assisted ventilation or likely to require assisted ventilation during the study based on the judgment of the investigator.
  3. Subjects with total IgG levels ≤ 6 g/L at screening.
  4. Subjects with a B-cell count ≤ 5% of the lower limit of normal at screening.
  5. Received high-dose intravenous methylprednisolone within 4 weeks prior to the screening period.
  6. Received intravenous immunoglobulin, plasma exchange, or immunoadsorption treatment within 4 weeks prior to the screening period.
  7. Received a vaccination within the first 4 weeks of the screening period or planned during the study.
  8. Using of a monoclonal antibody or drug not mentioned above that has immunomodulatory effects within 3 months or 5 half-lives (whichever is longer) prior to the screening period.
  9. Subject is known to be allergic to any component of the study drug or any other FcRn drug or contrast medium for enhanced MRI.
  10. Subject is known to have to taking methylprednisolone (for subjects in A and B group).
  11. Subjects with active infections (including unresolved or inadequately treated infections, including active tuberculosis) as assessed by the investigator.
  12. Subjects with positive screening tests for and C who have received live or within 6 weeks prior to baseline.
  13. Subjects is known unable to taken MRI.
  14. Subjects is known to have other ophthalmic disease that affect vision as assessed by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Efgartigimod+IVMP group

    Patients will receive efgartigimod alpha via intravenous infusion at a dose of 10 mg/kg, each infusion lasting approximately 2 hours, on Week 0, 1, 2 and 3. Efgartigimod should be administered no later than the second day after initiation of high-dose intravenous methylprednisolone therapy. This is delivered intravenously at a dosage of 1,000 mg/day for five consecutive days, which is then reduced to 500 mg/day for the next three days, followed by 240 mg/day for another three days, and then 120 mg/day for an additional three days. Subsequently, the treatment shifts to oral prednisone, starting with 60 mg daily for seven days, then decreasing to 50 mg daily for the next seven days, followed by 40 mg daily for another seven days. Afterward, the prednisone dosage is reduced by 5 mg every two weeks until it reaches 10 mg. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.

    Drug: Efgartigimod Alfa Injection · Drug: High-dose intravenous methylprednisolone

  • Experimental
    IVMP group

    Patients will be treated with injectable methylprednisolone sodium succinate as described in Arm A. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.

    Drug: High-dose intravenous methylprednisolone

  • Other
    Efgartigimod group

    Patients will be treated with efgartigimod alpha injection via intravenous infusion at a dosage of 10 mg/kg, with each session lasting approximately 2 hours, on Week 0, 1, 2 and 3. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.

    Drug: Efgartigimod Alfa Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Neurological Disability - Expanded Disability Scale Score

    The Kurtzke Expanded Disability Status Scale (EDSS) was developed to measure the disability status of subjects with demyelinating disease. It allows an objective quantification of the level of functioning that could be widely and reproducibly used by researchers and health care providers. The EDSS provides a total score on a scale that ranges from 0 to 10 where 0 is normal and 10 is deceased. Increasing disability is reflected in an increasing EDSS score.

    Time frame: Acute nadir to week4

Secondary outcomes

  1. Change of FS score and MRC score at Week 12.

    To evaluate changes in neurologic outcomes in subjects with acute attacks in subjects with AQP4-IgG antibody-positive neuromyelitis optica spectrum disorders who are treated with efgartigimod + IVMP versus IVMP alone at Week 12. The Functional System (FS) was developed to measure the function of seven systems, including visual functions (score 0-6), brainstem functions (score 0-5), pyramical functions (score 0-6), cerebellar functions (score 0-5, X is the condition that pyramidal weakness (BMRC grade 3 or worse in limb strength) or sensory deficits interfere with cerebellar testing), sensory functions (score 0-6), bowel and bladder functions (score 0-6), cerebral functions (score 0-5). Increasing disability of different functional system is reflected in an increasing FS score. Muscle Power Assessment (MRC) was developed to assess the muscle power of limbs. A score of 0-5 was used to grade the power. Increasing disability of muscle power is reflected in an decreasing MRC score.

    Time frame: Baseline to week 12.

  2. Change of EDSS score, FS score, and MRC score at Week 4 and 24.

    To evaluate changes in neurologic outcomes in subjects with acute attacks in subjects with AQP4-IgG antibody-positive neuromyelitis optica spectrum disorders who are treated with efgartigimod + IVMP versus IVMP alone at Week 4 and Week 24. The EDSS score, FS score MRC score was described as in outcome 2.

    Time frame: Baseline to Week 4 and Week 24.

  3. Change of EQ-5D-5L score.

    To evaluate changes in quality of life in subjects at Week 4, 12, 24.

    Time frame: Baseline to Week 4, 12 and 24.

  4. Change of high-contrast visual acuity in subjects with acute optic neuritis.

    To evaluate changes in vision outcomes (High contrast visual acuity ) in subjects with acute optic neuritis post-treatment at Week 4, 12, 24.

    Time frame: Baseline to Week 4, 12 and 24.

  5. Change of OCT measurements in subjects with acute optic neuritis.

    To evaluate changes in vision outcomes (OCT measures) in subjects with acute optic neuritis post-treatment at Week 4, 12, 24.

    Time frame: Baseline to Week 4, 12 and 24.

  6. The proportion of participants requiring rescue treatment during the study period.

    To evaluate the proportion of subjects requiring rescue treatment during the study period.

    Time frame: Baseline to Week 24.

  7. The incidence of adverse events in the subjects during the study period.

    To evaluate the safety and tolerability of efgartigimod +IVMP versus IVMP alone.

    Time frame: Baseline to Week 24.

  8. The vital signs, clinical laboratory indices, and electrocardiogram records of the subjects during the study period.

    To evaluate the vital signs, clinical laboratory parameters and electrocardiograms during the study.

    Time frame: Baseline to Week 24.

Other outcomes

  1. Change of serum total IgG levels.

    To evaluate changes in serum levels of total IgG in participants post-treatment at Week 4, 12, 24.

    Time frame: Baseline to Week 4, 12 and 24.

  2. Change of serum AQP4-IgG antibody levels.

    To evaluate changes in serum levels of AQP4-IgG antibodies in participants post-treatment at Week 4, 12, 24.

    Time frame: Baseline to Week 4, 12 and 24.

  3. Change of serum GFAP and NfL.

    To evaluate changes in serum GFAP and NfL levels in participants after treatment at Week 4, 12 and 24.

    Time frame: Baseline to Week 4, 12 and 24.

  4. Change of the size and extent of MRI lesions.

    To evaluate changes in spinal cord imaging in participants with acute myelitis following a course of efgartigimod + IVMP versus IVMP alone at Week 4, 12 and 24.

    Time frame: Baseline to Week 4, 12 and 24.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2024; primary completion for Dec 2025, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2024
First posted
Jul 11, 2024
StartEst.
Jul 5, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06497374
Lead sponsor
Tianjin Medical University General Hospital
Responsible party
Fu-Dong Shi (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Jul 11, 2024
Start date
Jul 5, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jul 11, 2024

Study contacts

Fu-Dong Shi
Contact
fshi@tmu.edu.cn
+8602260814587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Methylprednisolone

Start the discussion